感冒退热合剂联合重组人干扰素α1b治疗儿童乙型流感疗效

Curative effect of cold and fever mixture combined with recombinant human interferon α1b on influenza B in children

目的 观察感冒退热合剂联合雾化重组人干扰素α1b治疗儿童乙型流感的疗效。方法 选择2021年1月—2022年6月武汉市中医医院收治的80例乙型流感患儿作为研究对象,随机分为两组各40例。对照组予雾化重组人干扰素α1b治疗,研究组予感冒退热合剂联合雾化重组人干扰素α1b治疗。评价两组疗效、恢复情况[鼻咽拭子乙型流感病毒抗原(IBV-Ag)是否转阴,血清淀粉样蛋白A(SAA)、C反应蛋白(CRP)和体温是否恢复正常]和安全性,比较两组患儿治疗前后免疫指标(CD3^(+)、CD4^(+)、CD8^(+))、炎症因子[血清白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素4(IL-4)、γ干扰素(IFN-γ)]水平变化。结果 治疗后研究组总有效率为90.00%,明显高于对照组的70.00%(P <0.05);研究组的IBV-Ag转阴比例,以及血清SAA、CRP和体温正常比例均显著高于对照组(P <0.05)。治疗后,两组患儿的CD3^(+)、CD4^(+)均较前明显升高(P <0.05),血清IL-6、TNF-α、IL-4、IFN-γ水平与CD8^(+)则均较前明显降低(P <0.01),且研究组上述指标均优于对照组(P <0.05)。两组不良反应总发生率差异无统计学意义(P> 0.05)。结论 感冒退热合剂联合雾化重组人干扰素α1b治疗儿童乙型流感效果良好,能促进患儿恢复,增强机体免疫,改善炎症因子水平,且安全性尚可。

Objective To observe the curative effect of cold and fever-curing mixture combined with atomized recombinant human interferonα1b in the treatment of influenza B in children.Methods A total of 80 children with influenza B admitted to Wuhan Hospital of Traditional Chinese Medicine from January 2021 to June 2022 were randomly divided into two groups with 40 cases in each group. The control group was treated with atomized recombinant human interferon α1b, and the study group was treated with cold and fever mixture combined with atomized recombinant human interferon α1b. To evaluate the efficacy, recovery [whether influenza B virus antigen (IBV-Ag) in nasopharyngeal swabs turned negative, whether serum amyloid A (SAA), C-reactive protein (CRP) and body temperature returned to normal] and safety of the two groups. The changes of immune indexes (CD3^(+), CD4^(+), CD8^(+)) and inflammatory factors [serum interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), interleukin-4 (IL-4), interferon γ (IFN-γ)] before and after treatment were compared between two groups. Results The total effective rate of the study group was 90.00%, which was significantly higher than that of the control group 70.00% after treatment (P<0.05);and the proportion of IBV-Ag to negative and the proportion of SAA, CRP and normal body temperature in the study group were significantly higher than those in the control group (P<0.05). After treatment, the levels of CD3^(+) and CD4^(+) in both groups were significantly higher than those before treatment (P<0.05), while the levels of IL-6, TNF-α, IL-4, IFN-γ and CD8^(+) in serum were significantly lower than those in the previous year (P<0.01), and the above indexes in the study group were significantly better than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P>0.05). Conclusion The treatment of influenza B in children with cold and fever mixture combined with atomized recombinant human interferon α1b has good effect, can promote the recovery of children, enhance immunity, improve the level of inflammatory factors, and is safe.